Patheon, Inc. names Mark Kontny, Ph.D., as its President of Global
Pharmaceutical Development Services and its Chief Scientific Officer

TORONTO, April 15 /CNW/ - Patheon, Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Mark Kontny, Ph.D. has joined the company as its President of Global Pharmaceutical Development Services (PDS) and as its Chief Scientific Officer. Dr. Kontny joins Patheon from Abbott Laboratories, where he was Divisional Vice President, Global Pharmaceutical and Analytical Sciences for their global pharmaceutical research and development organization.

"Mark has developed a well deserved reputation for combining strong technical abilities with excellent leadership skills. We look forward to him quickly integrating into the Patheon leadership team and helping us drive our PDS business to an even higher performance level," said Wes Wheeler, Patheon's CEO and President.

"I am delighted to join Patheon and look forward to leading the PDS organization to provide best in class development services to accelerate customer molecules to market," said Dr. Kontny.

Mr. Wheeler added, "Dr. Doug Mendenhall, while stepping down as Interim President of our PDS business and Chief Scientific Officer roles, will continue with the company on a part-time basis providing advice and assistance in implementing our technology and alliance strategies. I look forward to Dr. Mendenhall's continued counsel as we continue to grow the company."

Dr. Kontny built his career over nearly 25 years, taking on increasing responsibilities at Ventaira Pharmaceuticals, Boehringer-Ingelheim, Monsanto-G.D. Searle, Pharmacia and Pfizer. He completed his Bachelors and Masters degrees in Pharmacy, as well as his Ph.D. in Pharmaceutics at the University of Wisconsin-Madison.

ABOUT PATHEON

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of 11 facilities, and eight development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

%SEDAR: 00001700E

For further information: Mr. Wes Wheeler, President and Chief Executive Officer, Tel: [phone], Email: [email protected]; Mr. Eric Evans, Chief Financial Officer, Tel: [phone], Email: [email protected]; Ms. Wendy Wilson, Investor Relations, Tel: [phone], Email: [email protected]